PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93024C00016Development of covalently BOUND hyaluronic ACID — Design-Zyme LLC

Design-Zyme LLC holds $3.0M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 16 offers. Set-aside status: SBA. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Niaid

Awarding office

Design-Zyme LLC

Recipient

Sep 29, 2027

PoP end

$3M

Obligated

$3M

Potential

541714

NAICS

AN12

PSC

SBA

Set-aside

16 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Design-Zyme LLC — $90

Contract facts

SBA

Contract number75N93024C00016

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentDesign-Zyme LLC

CAGE7KSG8

UEIRM33XDX5RRG4

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN12

Place of performanceLAWRENCE KS

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

Related solicitationPHS2024-1

PoP startSep 30, 2024

PoP end (current)Sep 29, 2027

Obligated$3M

Current value$3M

Potential value$3M

DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE is a federal SBA award for National Institutes Of Health Niaid held by Design-Zyme LLC. Estimated value $3M ($3M obligated). Current period of performance ends Sep 29, 2027. Last award drew 16 bidders. Place of performance: LAWRENCE KS. Related solicitation PHS2024-1.

DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE

Recompete timing

Public

● Expiring in 387 days

Current PoP ends Sep 29, 2027 (387 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Design-Zyme LLC — $3.0M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$3.0M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93024C00016?

75N93024C00016 (Development of covalently BOUND hyaluronic ACID) is a National Institutes Of Health Niaid award with a potential value of $3M, currently held by Design-Zyme LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93024C00016?

National Institutes Of Health Niaid awarded 75N93024C00016 to Design-Zyme LLC (potential $3M).

Who is the incumbent on 75N93024C00016?

Design-Zyme LLC is the incumbent with $3.0M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.

When does Design-Zyme LLC’s 75N93024C00016 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N93024C00016 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 26, 2026 · refreshed monthlyLatest procurement action Jul 17, 2026